drugset / Trial / NCT04249687
Treatment of Moderate to Severe Lateral Canthal Lines
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The objective of the study is to evaluate the efficacy and safety of a single dose of QM1114-DP compared to placebo for the treatment of moderate to severe LCL.
Timeline
- Start
- 2020-02-10
- Primary completion
- 2020-09-25
- Completion
- 2021-02-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Botulinum toxin | Protein / enzyme biologic | — | Intramuscular |